Efficient Recreation of t(11;22) EWSR1-FLI1⁺ in Human Stem Cells Using CRISPR/Cas9

Raul Torres-Ruiz,1,3,* Marta Martinez-Lage,1 Maria C. Martin,1 Aida Garcia,2 Clara Bueno,3 Julio Castaño,3 Juan C. Ramirez,4 Pablo Menendez,4,5,6 Juan C. Cigudosa,1 and Sandra Rodriguez-Perales1,*
1Molecular Cyto genetics Group, Human Cancer Genetics Program, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid 28029, Spain
2Hematopoietic Innovative Therapies Division, Centro Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT)-Centro Investigaciones Biomédicas Red Enfermedades Raras (CIBERER), Madrid 28040, Spain
3Department of Biomedicine, Josep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, Barcelona 08036, Spain
4VIVEBioTECH, San Sebastián 20009, Spain
5Institució Catalana de Recerca i Estudis Avançats (ICREA), Passeig Lluis Companys
6Centro de Investigación Biomédica en Red de Cáncer (CIBER-ONC), ISCIII Barcelona 08010, Spain
*Correspondence: rtorres@cnio.es (R.T.-R.), srodriguezp@cnio.es (S.R.-P.)
http://dx.doi.org/10.1016/j.stemcr.2017.04.014

SUMMARY

Efficient methodologies for recreating cancer-associated chromosome translocations are in high demand as tools for investigating how such events initiate cancer. The CRISPR/Cas9 system has been used to reconstruct the genetics of these complex rearrangements at native loci while maintaining the architecture and regulatory elements. However, the CRISPR system remains inefficient in human stem cells. Here, we compared three strategies aimed at enhancing the efficiency of the CRISPR-mediated t(11;22) translocation in human stem cells, including mesenchymal and induced pluripotent stem cells: (1) using end-joining DNA processing factors involved in repair mechanisms, or (2) ssODNs to guide the ligation of the double-strand break ends generated by CRISPR/Cas9; and (3) all-in-one plasmid or ribonucleoprotein complex-based approaches. We report that the generation of targeted t(11;22) is significantly increased by using a combination of ribonucleoprotein complexes and ssODNs. The CRISPR/Cas9-mediated generation of targeted t(11;22) in human stem cells opens up new avenues in modeling Ewing sarcoma.

INTRODUCTION

Chromosomal translocations are common genomic events in cancer and are the initiating event in many leukemias and sarcomas (http://cgap.nci.nih.gov/Chromosomes/Mitelman). Cancer-associated chromosomal translocations generate novel chromosomes, placing genes in new linkage relationships that can result in the generation of fusion genes or the overexpression of proto-oncogenes. Given their contribution to cancer pathogenesis, chromosomal translocations have been widely studied to better understand the mechanisms involved in their formation and the downstream molecular consequences (Chen et al., 2010; Guryanova and Levine, 2013; Rodriguez-Perales et al., 2015). Genetically modified cells and animal models are essential tools for studying both the function of chromosomal translocations and the initiating oncogenic events in cancer. Targeted chromosomal translocations have been generated de novo in human and mouse models using technologies based on P1 Cre-loxP (Forster et al., 2005; Van Deursen et al., 1995), zinc-finger nucleases (ZFN) (Brunet et al., 2009), and transcription activator-like effector nucleases (TALENs) (Piganeau et al., 2013); these approaches generate two derivative chromosomes while maintaining the spatial architecture and regulatory elements of the genomic rearrangement.

The prokaryotic clustered regularly interspersed short palindromic repeats (CRISPR)/Cas9 system (Jinek et al., 2012) has been adapted to induce specific double-strand breaks (DSBs) in the genomes of many species (Cong et al., 2013; Mali et al., 2013). This technology has facilitated and accelerated genome engineering through the targeting of specific locations in the genome guided by single-guide RNA (sgRNA) (Jinek et al., 2012). A key advantage of the CRISPR/Cas9 genome editing over more traditional gene-targeting strategies is its high efficiency, which renders common selection procedures unnecessary (Li et al., 2014; Yang et al., 2013). The CRISPR/Cas9 system was recently adapted to induce chromosomal translocations in vitro (Torres et al., 2014b) and in vivo in mouse models (Blasco et al., 2014; Maddalo et al., 2014). These approaches were based in the simultaneous use of two sgRNAs, resulting in two targeted DSBs that when resolved by the DNA repair machinery can generate specific chromosomal translocations. However, although CRISPR/Cas9 technology considerably increases the efficiency of chromosomal translocations, identification of a bona fide targeted clone requires screening of many clones, especially with stem cells.

Cancer is generally studied after the transformation events are completed, and patient samples are therefore not amenable to analysis of the mechanisms through which cancer-specific chromosomal translocations initiate
oncogenesis. CRISPR/Cas9 genome editing has thus emerged as a tool with enormous potential for assisting in the generation of in vitro and in vivo cancer models, and its combination with human embryonic or adult stem cells will likely prove invaluable for studying the molecular and cellular origin of human disease. However, making this approach feasible requires alternatives to increase the specificity and efficiency of genome targeting in human stem cells.

Here we have compared three strategies for enhancing the efficiency of CRISPR/Cas9-mediated chromosomal translocations in human stem cells, including mesenchymal stem cells (hMSCs) and induced pluripotent stem cells (hiPSCs): (1) promoting chromosomal translocations with end-joining DNA processing factors involved in classical non-homologous end-joining (cNHEJ) and alternative end-joining (altNHEJ); (2) using single-stranded oligodeoxynucleotides (ssODNs) to guide the ligation of DSB ends generated by CRISPR/Cas9; and (3) all-in-one plasmid or ribonucleoprotein (RNP) complex-based approaches. We report that targeted chromosomal translocations are generated more efficiently when the all-in-one plasmid, RNP complex, and ssODN-based approaches are used, with the most efficient strategy being the combination of RNP complexes with translocation-ssODNs. These results represent a significant technical advance toward the induction of targeted chromosomal translocations in human stem cells.

RESULTS

The All-in-One Plasmid Increases Genome-Editing Efficiency

The CRISPR/Cas9 system was adapted to induce targeted chromosomal translocations using a two-plasmid approach for the co-expression of two sgRNAs (pLVX-sgRNA<sup>fl</sup>-Cas9 and pLVX-sgRNA<sup>hr</sup>-Cas9) (Torres et al., 2014b). Although this approach allows for efficient generation of chromosomal translocations in easy-to-transfect cell lines, the recreation of such translocations in human stem cells remains a challenge. Thus, improved methods need to be developed to increase the specificity and efficiency of genome targeting in human stem cells. To maximize the concurrent delivery of CRISPR components, we established a Cas9 all-in-one expression plasmid (pLVX-U6-sgRNA<sup>fl-H1</sup>-sgRNA<sup>hr-Cas9</sup>-2A-eGFP; hereafter pLV-U6<sup>fl-H1<sup>hr-C9G</sup></sup>) (Figure 1A) that drives similar sgRNA expression levels from two different RNA polymerase III promoters (U6 and H1) and a simultaneously regulated expression of Cas9 and GFP proteins by a 2A self-cleaving peptide. As a test model we focused on the t(11;22)(q24;q12) chromosomal translocation, a hallmark of Ewing sarcoma believed to occur in hMSCs (Delattre et al., 1994). Transfection optimization assays first showed that nucleofection, an electroporation-based transfection method, is the most efficient delivery approach for hMSCs, and an extremely robust transfection approach for HEK293 cells (Figure S1). Thus, HEK293 cells and hMSCs were nucleofected with pLVX-sgRNA<sup>fl-Cas9</sup> plus pLVX-sgRNA<sup>hr-Cas9</sup> or with pLV-U6<sup>fl-H1<sup>hr-C9G</sup></sup> (2 μg of plasmid), and DNA was isolated after 72 hr for analysis of the chromosomal translocation involving EWSR1 and FLI1 loci. The t(11;22)(q24;q12) translocation was successfully reproduced in both HEK293 cells and hMSCs (Figure 1B). Fluorescence in situ hybridization (FISH) assays using dual-fusion probes 48–72 hr after transfection revealed significantly higher levels of targeted chromosomal translocations with the all-in-one vector than with the two-plasmid system (2.1-fold from 0.48% to 1.04%) in HEK293 and 6.5-fold from 0.11% to 0.68% in hMSCs (Figure 1C and Table S1). The presence of the balanced translocation at the genome level was confirmed by junction genomic PCR and Sanger sequencing (Figures 1D and S2).

To further improve the all-in-one approach, we incorporated a second nuclear localization signal (NLS) at the 5′
end of the Cas9 coding region of the pLV-U6sgRNA<sup>1</sup>-H1sgRNA<sup>2</sup>-C9G all-in-one plasmid co-expressing sgRNAs targeting introns in EWSR1 (sgE1) and FLI1 (sgF2) and expressing Cas9 protein. The middle schemes show the location of the regions targeted by sgE1 and sgF2 sgRNAs in the t(11;22)/EWSR1-FLI1 chromosomal translocation: EWSR1 intron 7 (sgE1) and FLI1 intron 4 (sgF2). The lower schemes show PCR oligonucleotide positions and PCR product sizes. The U6, H1, and CMV promoters are represented as black arrows. LTR, long terminal repeat; P2A, 2A self-cleaving peptide; EGFP, enhanced green fluorescent protein; WPRE, woodchuck post-transcriptional regulatory element.

(B) Representative FISH images obtained with a dual-color dual-fusion probe (EWSR1 in green and FLI1 in red), showing HEK293 and hMSCs positive and negative for t(11;22). Arrows indicate fusion signals corresponding to the junction regions. Interphase nuclei are counterstained with DAPI. Scale bars, 10 μm.

(C) Fold change in the number of FISH-identified t(11;22)<sup>+</sup> HEK293 and hMSCs obtained using the all-in-one plasmid approach (one plasmid) versus the two-plasmid approach. Data are means ± SEM (n = 3 independent experiments); **p < 0.01, ***p < 0.001, unpaired Student’s t test.

(D) Top: agarose gel electrophoresis of translocation-specific PCR products from pooled HEK293 and hMSC samples. Bottom: representative Sanger sequencing chromatogram showing the breakpoint region in the EWSR1-FLI1 fusion gene mapped at der(22) in hMSCs.

Figure 1. Validation of the All-in-One Cas9 CRISPR Plasmid in HEK293 and hMSCs

(A) pLV-U6sgRNA<sup>1</sup>-H1sgRNA<sup>2</sup>-C9G all-in-one plasmid co-expressing sgRNAs targeting introns in EWSR1 (sgE1) and FLI1 (sgF2) and expressing Cas9 protein. The middle schemes show the location of the regions targeted by sgE1 and sgF2 sgRNAs in the t(11;22)/EWSR1-FLI1 chromosomal translocation: EWSR1 intron 7 (sgE1) and FLI1 intron 4 (sgF2). The lower schemes show PCR oligonucleotide positions and PCR product sizes. The U6, H1, and CMV promoters are represented as black arrows. LTR, long terminal repeat; P2A, 2A self-cleaving peptide; EGFP, enhanced green fluorescent protein; WPRE, woodchuck post-transcriptional regulatory element.

(B) Representative FISH images obtained with a dual-color dual-fusion probe (EWSR1 in green and FLI1 in red), showing HEK293 and hMSCs positive and negative for t(11;22). Arrows indicate fusion signals corresponding to the junction regions. Interphase nuclei are counterstained with DAPI. Scale bars, 10 μm.

(C) Fold change in the number of FISH-identified t(11;22)<sup>+</sup> HEK293 and hMSCs obtained using the all-in-one plasmid approach (one plasmid) versus the two-plasmid approach. Data are means ± SEM (n = 3 independent experiments); **p < 0.01, ***p < 0.001, unpaired Student’s t test.

(D) Top: agarose gel electrophoresis of translocation-specific PCR products from pooled HEK293 and hMSC samples. Bottom: representative Sanger sequencing chromatogram showing the breakpoint region in the EWSR1-FLI1 fusion gene mapped at der(22) in hMSCs.
that an extra NLS increases the nuclear localization of the Cas9 (Figure 3B). Western blot confirmed similar expression of Cas9 protein in both 1xNLS and 2xNLS conditions (Figure S4B). On-target T7 endonuclease analysis of cells edited with pLV-U6\textsuperscript{H1\textsuperscript{H2}}-C9G and sgRNA-F2 revealed that 2xNLS Cas9 plasmid increases the rate of genomic cleavage 12-fold (from 3.3% to 37.2%) (Figure 3C). FISH analysis revealed that the 2xNLS version of pLV-U6\textsuperscript{H1\textsuperscript{H2}}-C9G significantly increased the frequency of cells harboring the t(11;22) translocation 3.6-fold in HEK293 cells (from 0.50% to 1.83%) and 7.1-fold in hMSCs (from 0.06% to 0.46%) (Figure 3D and Table S1). The high percentage of indel formation (37.2%) at the on-target site revealed that NHEJ is still more efficient at rejoining the DSBs of the broken ends than at generating chromosomal translocations.

**Guided Rejoining of DSB by ssODN Donor Templates Enhances Targeted Generation of t(11;22) Translocation**

The high rate of rejoining at the EWSR1 and FLI1 target sites without induction of translocation prompted us to
investigate ways to further promote the t(11;22) translocation. Targeted integration or large deletions can be achieved by combining the CRISPR system with ssODN templates containing homology arms flanking the genomic modification site (Yoshimi et al., 2016). To facilitate the genomic translocation, we designed translocation-ssODN donors, hypothesizing that ssODNs would guide homologous-directed (HDR) rejoining of the translocation-derived chromosomes. We generated five different-length ssODNs (60–180 nt), each carrying the 5′ and 3′ portions complementary to the upstream and downstream regions of the der(22) derivative chromosome breakpoint (Figure 4A; nucleotide sequences are shown in Table S2). HEK293 cells were nucleofected with 2 μg of the plV-U6#1H1#2-C9G-2NLS all-in-one CRISPR vector and 200 pmol of translocation-ssODN donor. FISH analysis of translocation-editing efficiency 72 hr after nucleofection confirmed that co-nucleofection with ssODNs increased translocation frequency by 2-to 10-fold (from 0.11% to 1.11%) (Figure 4B). The highest increase was achieved with the 150-nt ssODN, with longer and shorter ssODNs being less efficient (Figure 4B and Table S1). We next tested the combined use of two 150-nt translocation-ssODN donors, one for each derivative chromosome. Delivery into HEK293 cells of two translocation-ssODNs yielded limited improvement in translocation frequency over that achieved with a single ssODN (from 1.24% to 1.57% to 2.02%) (Figure 4C). However, delivery of two translocation-ssODNs to hMSCs produced an 11-fold increase in the translocation frequency compared with absence of ssODN (from 0.27% to 2.67%) (Figure 4D and Table S1), suggesting that two translocation-ssODN donors, one for each derivative chromosome, enhance the frequency of t(11;22) in stem cells.

Co-transduction with End-Joining DNA-Processing Factors Enhances Targeted Generation of the t(11;22) Translocation in hMSCs

Targeted gene disruption can be increased by co-transfection with DNA end-processing enzymes (Certo et al., 2012), and the DNA end-joining mechanism influences the efficiency of translocation generation. To study the
ability of different DNA end-joining factors to promote CRISPR-targeted translocations in the rejoining of the CRISPR-induced DSBs, we ectopically expressed genes involved in classical or alternative NHEJ repair. HEK293 cells and hMSCs were both co-nucleofected with the pLV-U6#1H1#2-C9G-2xNLS all-in-one CRISPR plasmid and a vector driving expression of one of the following end-joining DNA processing factors: AICDA, ARTEMIS, DCLREI, FEN1, MRE11, TREX2, or PARP1. FISH analysis showed that none of these factors had a substantial effect on translocation generation in HEK293 cells (Figure 5A). However, TREX2 and PARP1 induced a 2.2-fold increase in targeted translocations in hMSCs (from 0.33% to 0.72% or 0.73%, respectively) (Figure 5B and Table S1). Importantly, overexpression of end-processing factors did not induce cell toxicity (data not shown).

**Cas9 Ribonucleoproteins Robustly Enhance Targeted t(11;22) Translocation in hMSCs**

Recent studies in a variety of human stem cells have demonstrated that recombinant Cas9 protein can be efficiently delivered by electroporation or nucleofection (Chen et al., 2013; Gaj et al., 2012; Kim et al., 2014; Liu et al., 2015; Ramakrishna et al., 2014). Moreover, the use of Cas9 RNPs (purified recombinant Cas9 protein complexed with an in vitro transcribed sgRNA) further
increases genome-editing efficiency and is associated with a low rate of off-target effects (Liang et al., 2015). We sought to increase the efficiency of targeted t(11;22) translocations in hMSCs by simultaneously nucleofecting two in vitro-assembled RNP complexes targeting both breakpoint regions formed by a combination of a 3xNLS Cas9 nuclease (IDT) and in vitro transcribed sgRNA#1 or sgRNA#2. We first optimized the amount of RNPs by nucleofecting GFP-expressing HEK293 cells with increasing doses of GFP-targeting Cas9-sgRNA RNPs (0.5–4 μg). FACS analysis 72 hr post transfection showed that the percentage of GFP+ HEK293 cells was optimal after nucleofection with 2 μg of GFP-targeting Cas9-sgRNA RNPs (0.5–4 μg). FACS analysis 72 hr post transfection showed that the percentage of GFP+ HEK293 cells was optimal after nucleofection with 2 μg of GFP-targeting Cas9-sgRNA RNPs (Figure S5). We therefore compared the efficiency of RNPs delivery with 2 μg of RNPs versus 2 μg of pLV-U6^Cas9^H1^sgRNA_2-C9G all-in-one CRISPR vector. FISH analysis 72 hr after nucleofection revealed that, compared with plasmid-based Cas9/sgRNA expression, translocation editing with the RNP approach was 9-fold more efficient in HEK293 cells (from 0.39% to 3.66%) and 12-fold more efficient in hMSCs (from 0.08% to 1.00%) (Figure 5C). The increased frequency of t(11;22)+ cells when the RNPs were used was not associated with off-target effects at the predicted top off-target sites (http://crispr.mit.edu/ and https://benchling.com/) as determined by T7 endonuclease assay (Figure S3). Long-term culture assay coupled with FISH analysis of three independent t(11;22)+ HEK293 cellular clones demonstrated stability of the derivative chromosomes (data not shown).

The outcome of the CRISPR/Cas9 optimization strategies undertaken in HEK293 cells and hMSCs prompted us to evaluate combinations of Cas9 RNP complexes with ssODNs or end-joining DNA processing factors for the generation of targeted t(11;22) translocation. hMSCs were nucleofected with RNPs alone or in combination with translocation-ssODNs or with the PARP1 or TREX factors. FISH analysis showed that the combination of RNPs and ssODNs increased the t(11;22) frequency in hMSCs by 2-fold (from 0.84% to 1.65%) (Figure 5D and Table S1). Interestingly, neither TREX2 nor PARP1 enzymes enhanced the efficiency of targeted t(11;22) translocation.

**Generation of t(11;22) Translocation in Human iPSCs**

In line with previous studies (Kovar et al., 2016), despite being possible to induce the t(11;22) in hMSCs over the short term, the fusion gene was not compatible with hMSC viability/homeostasis and the t(11;22)-edited hMSCs were progressively lost in culture (data not shown). Because Ewing sarcoma is composed of poorly differentiated cells...
of unknown origin (Kovar et al., 2016), we next sought to generate the t(11;22) translocation in human iPSCs. These difficult-to-target cells are an invaluable biological tool for disease modeling and biomedical research (Sancho-Martinez et al., 2016). We first checked the on-target cleavage of hiPSCs edited with 2xNLS Cas9 plasmid or with 3xNLS RNP complexes targeting both breakpoint regions. Open triangles depict the full-length PCR product and filled triangles the digestion products. (B) Agarose gel electrophoresis of translocation-specific PCR products from pooled hiPSC samples. The Sanger sequencing chromatogram shows the breakpoint region in the EWSR1-FLI1 fusion gene mapped at der(22). (C) Representative FISH images obtained with a break-apart EWSR1 probe showing hiPSCs positive and negative for t(11;22) generated with Cas9 RNP and ssODNs. Arrows indicate separated signals corresponding to the der(22) and der(11) breakpoint regions. Interphase nuclei are counterstained with DAPI. Scale bars, 10 μm. (D) Fold-change variation in the number of engineered t(11;22) translocations determined by FISH in hiPSCs transfected with the 2xNLS-plV-U6#1H1#2-C9G plasmid approach or with the RNP + ssODNs approach. Data are means ± SEM (n = 3 independent experiments); **p < 0.01, unpaired Student’s t test. (E) Immunostaining of t(11;22) positive and negative hiPSC colonies for the pluripotency markers OCT4 and SSEA4. Scale bars, 200 μm.
Sanger sequencing 72 hr after nucleofection revealed the generation of the t(11;22) translocation in the hiPSC population (Figure 6B), a result confirmed by FISH analysis (Figure 6C). FISH analysis confirmed that co-nucleofection with RNPs and ssODNs increased translocation frequency by 3.2-fold (from 0.42% to 1.39%) compared with the 2xNLS approach (Figure 6D). Importantly, hiPSCs were subcloned and a t(11;22) hiPSC clone was expanded for 8 weeks, revealing maintenance of the translocation (Figure 6E), with no differences in cell/colony morphology, expression of the pluripotency markers OCT4 and SSEA-4, and growth rate (Figure 6E).

**DISCUSSION**

We have developed an optimized and streamlined method for efficient engineering of targeted chromosomal translocations in human MSCs and iPSCs. We first generated an all-in-one plasmid system to co-express two sgRNAs, the *Streptococcus pyogenes* Cas9 flanked by two NLSs and an EGFP reporter. This all-in-one plasmid system enhanced successful delivery of CRISPR components and allowed FACS selection of transfected cells, thus maximizing the frequency of cells targeted by CRISPR/Cas9 and improving nuclear protein uptake and its subsequent genome engineering activity without observed off-target effects. Unlike other strategies, our expression vector provides simultaneous expression of CRISPR elements and an improved nuclear uptake of the Cas9 protein. Compared with the all-in-one 1xNLS approach, the 2xNLS version yielded 3.6-fold and 7.1-fold higher translocation rates for the Ewing sarcoma t(11;22) translocation in HEK293 cells and human MSCs, suggesting that this strategy is a robust tool for targeted translocations. The different genome-editing efficiencies in HEK293 cells and hMSCs clearly reflect differences in biology and genetic background between unstable cell lines and human stem cells.

To further increase targeted translocation with the CRISPR/Cas9 system, we devised two improvements. The first approach involves co-nucleofection of two translocation-ssODNs for efficient guidance of the broken chromosomes. Donor ssODNs composed of homology arms flanking the genomic modification site have been used to increase targeting efficiencies in human stem cells (Chen et al., 2011; Kim and Kim, 2014; Yang et al., 2013), and recent reports exploited ssODNs to improve CRISPR deletion approaches (Yoshimi et al., 2016). We therefore hypothesized that donor ssODN templates containing homology arms flanking the junction region of a translocation-derived chromosome breakpoint would guide the rejoinder of the derivative chromosome, thus facilitating translocation. The concurrent use of two 150-nt-long ssODN donor translocation templates complementary to each derivative chromosome yielded an 11-fold increase in hMSC translocation efficiency. This effect was crucially influenced by ssODN donor length. Shorter ssODNs might be too weak to guide HDR, whereas longer ssODNs might be less accessible to the genome repair machinery, perhaps due to secondary structure constraints.

Further details of this mechanism will await future studies on the dynamics of chromosomal translocations and the role of HRD.

The second approach is based on the co-expression of end-joining DNA-processing factors. Although the breakage mechanisms of chromosomal translocations are not completely understood, the rejoining mechanism is usually via NHEJ, the predominant DSB repair pathway when no DNA template is available. NHEJ is mediated by two subpathways, classical (cNHEJ), initiated by the Ku complex, and alternative (altNHEJ), initiated by poly ADP-ribose polymerase 1 (PARP1); each subpathway has distinct mutational consequences (Audebert et al., 2004; Castaño et al., 2016; Howard et al., 2015). The cNHEJ repair pathway suppresses the formation of chromosome translocations but sometimes induces sequence alterations at the junction regions. The altNHEJ pathway operates when the cNHEJ pathway is inactivated, and is associated with a higher probability of chromosome translocations and the generation of larger sequence alterations at junction breakpoints (Iliakis et al., 2015). Recent reports suggest that the altNHEJ pathway typically recognizes sequence microhomologies and is more translocation prone (Audebert et al., 2006; Certo et al., 2012; Wray et al., 2013), and this pathway has been linked to chromosome translocations in mouse cells, *Drosophila*, and yeast (McVey et al., 2004; Simsek and Jasin, 2010). Thus, altNHEJ seems to be responsible for the elimination from the genome of highly cytotoxic DNA DSBs, but at the cost of increasing the generation of translocations. However, it is unclear how one DSB-processing pathway is selected over the other. DNA end-processing factors involved in the cNHEJ and altNHEJ repair mechanisms have been used to improve the efficiency of gene disruption genome engineering in combination with ZFN and TALENs (Certo et al., 2012). Increases in mutagenesis rate of up to 25-fold have been reported upon coupling of ZFN endonucleases to DNA end-processing enzymes to drive targeted gene disruption (Certo et al., 2012).

We assessed whether co-expressing the CRISPR/Cas9 system with a panel of DNA end-processing factors could increase the targeted translocation rate. TREX2 and PARP1 produced a 2-fold increase in hMSC translocation rates, showing that coupling them with the CRISPR/Cas9 system provides an alternative route to increasing translocation rates in human stem cells.
Delivery of Cas9 protein in an RNP complex with the sgRNA avoids the need for in vivo transcription and translation. Moreover, this approach yields high expression shortly after nucleofection, followed by rapid degradation, thereby facilitating efficient gene editing while minimizing off-target rates. The good performance of the RNP approach in genome-engineering experiments (Liang et al., 2015) may be related to three factors: (1) the possibility to better control the complexing process in vitro, (2) the protection of the Cas9-complexed guide RNA from cellular degradation, and (3) the avoidance of DNA-based cellular toxicity. We found that the combined use of two RNP complexes greatly improves the efficiency of generating targeted translocations in hMSCs, yielding a 12-fold higher rate than the all-in-one plasmid approach. Translocation rates were further improved by co-nucleofecting RNPs and translocation-ssODNs, demonstrating a synergistic effect between these approaches. Surprisingly, translocation rate was not increased by the combined use of RNPs and DNA end-processing enzymes. This might be due to Cas9 RNP degradation preceding expression of the vector-encoded DNA end-processing factors.

Although a combination of 3xNLS-RNPs and ssODNs efficiently induced the t(11;22) translocation in hMSCs, this particular translocation was unstable in this cell type, and cells harboring this rearrangement were eventually lost in culture. This finding is in agreement with recent studies of Ewing sarcoma suggesting that MSCs might not represent the target cell-for-transformation in Ewing sarcoma (Kovar et al., 2016; Minas et al., 2016; Renouf et al., 2014; Rodriguez et al., 2011). We therefore attempted to induce the t(11;22) translocation in a less differentiated cell type. We chose hiPSCs because their pluripotent developmental early nature as iPSC derivatives constitutes a valid cellular system for disease modeling, including cancer development (Bueno et al., 2011; Menendez et al., 2006; Muñoz-López et al., 2016). Co-nucleofection with RNPs and translocation-ssODNs was able to induce targeted t(11;22) translocations in hiPSCs while maintaining the pluripotent phenotype. These t(11;22)-harboring iPSCs would therefore represent a major step forward in modeling the developmental impact of cancer-associated chromosomal translocations. It allows the investigation of the mechanistic basis and clonal properties of human Ewing sarcoma and would help us to understand the relative contributions of genetic and epigenetic developmental abnormalities to Ewing sarcoma, thus assisting in the integrated design of targeted therapies.

The coupled RNP-ssODN CRISPR/Cas9 approach presented here supports efficient targeted translocation induction, and enables rapid and efficient targeted translocation in hMSCs and hiPSCs. This approach is applicable to human stem cells, facilitating the combination of the power of human stem cell technology with the CRISPR/Cas9 genome-engineering system for cancer disease modeling. Translocations induced with the CRISPR/Cas9 system avoid potential complications associated with overexpression of fusion genes and transgene variegation while at the same time recreating the translocated genome architecture, including the spatial organization and regulatory elements. Moreover, the use of the CRISPR/Cas9 approach to reproduce chromosomal translocations allows the generation of isogenic cell lines, facilitating study of the effects of individual rearrangements.

The methodological approaches presented here for efficient generation of chromosomal translocations in hMSCs and hiPSCs have potential applications in a diverse range of cell types, and can be used to generate diverse genome rearrangements, including large deletions or inversions. RNPs can also be engineered and used for other gene-editing approaches. This strategy will likely facilitate cancer modeling with human stem cells and precise genome engineering for cell therapy approaches and drug-screening strategies, accelerating bench-to-bedside translation into preclinical studies.

**EXPERIMENTAL PROCEDURES**

**Cell Culture**

The HEK293 cell line (CRL-1573, ATCC) was maintained under standard conditions in DMEM (Lonza) supplemented with 10% fetal bovine serum (FBS), 1% GlutaMAX, and 10 mg/mL penicillin-streptomycin (all from Life Technologies). Umbilical cord blood-derived hMSCs (PCS-500-010, ATCC) were cultured in MesenPRO RS medium supplemented with MesenPRO growth supplement (Life Technologies). Cells were cultured at 37°C in a humidified atmosphere with 5% CO₂ and 20% O₂. hiPSCs were maintained under feeder-free conditions on Matrigel (BD Biosciences) in mTeSR1 medium (STEMCELL Technologies). Cultures were dispersed to single-cell suspensions using Accutase (STEMCELL). Cell survival before nucleofection was promoted with the Rho-associated kinase (ROCK) inhibitor Y-27632 (10 μM; Selleckchem). hiPSCs were generated in P.M.’s laboratory from human CD34+ cells from peripheral blood mononuclear cells using OKSM polyclstronic SeV vectors (Muñoz-López et al., 2016). hiPSC research was approved by the ISCIII Steering Committee on pluripotent stem cell research.

**Construction of Double-Guide Cas9-Encoding Plasmids, End-Joining DNA-Processing Factor Expression Plasmids, and ssODNs**

The parental plLV-sgRNA-Cas9 vector has been described elsewhere (Torres et al., 2014b). The CMV promoter was PCR-amplified from pcDNA3.1 (Life Technologies), and the H1 promoter was assembled from gBlocks gene fragments (IDT). The CMV and H1 promoters were cloned into plLV-sgRNA-Cas9. Two gBlocks gene fragments were synthesized to clone sgRNA#1 and sgRNA#2 in the
plasmids were included. In transfection experiments, 200 pmol of ssODN (IDT) or end-processing seed were seeded in a 24-well plate containing prewarmed medium. When cells were electroporated with 10^3 cells per 1 × 10^4 mm^2 electroporation plate, three 5-ms pulses of 1,400 V. After electroporation, cells were cultured in 4×10^3 ultramter DNA oligos. Nucleoplasmin NLS (Torres and Ramirez, 2009) was cloned at the 5' end of the Cas9 sequence, creating the pLV-U6^51-H^2-C9G vector (Figure 1A).

Cas9 Ribonucleoproteins
Recombinant Cas9 protein was obtained from IDT and sgRNAs were in vitro transcribed through runoff reactions by T7 RNA polymerase using the HiScribe T7 high-yield RNA synthesis kit (NEB). Transcribed sgRNAs were purified with a column purification kit (RNeasy mini kit, Qiagen), quantified, and quality checked by denaturing RNA gel electrophoresis. For generation of RNP complexes, Cas9 protein (1–8 μg) was premixed with in vitro transcribed sgRNA (0.5–8 μg) for 10 min at room temperature.

Transfection and Electroporation
Cells were transfected as previously described (Torres et al., 2014a). For electroporation, the Neon Transfection System was used (Thermo Fisher Scientific). Confluent hMSCs, hiPSCs, and HEK293 cells were trypsinized, resuspended in R solution, and electroporated using the following conditions. For hMSCs, 10-μL tips were used to electroporate 1 × 10^5 cells with a single 40-ms pulse of 990 V. For HEK293 cells, 4 × 10^5 cells were electroporated with 10-μL tips using three 10-μs pulses of 1,245 V. Finally, hiPSCs were electroporated with 10-μL tips using 2 × 10^5 cells with three 5-ms pulses of 1,400 V. After electroporation, cells were seeded in a 24-well plate containing prewarmed medium. When required, cells were sorted 72 hr post transfection. For co-transfection experiments, 200 pmol of ssODN (IDT) or end-processing plasmids were included.

Immunofluorescence
Immunofluorescence was carried out as previously described, with modifications (Torres and Ramirez, 2009).

Image Acquisition and Nucleus/Cytoplasm Ratio
Images were acquired on a TCS-SP5 confocal microscope from Leica microsystems using a 20× HCX PL APO dry objective (numerical aperture 0.7). Nucleus and cytoplasmic signal for each cell was segmented and quantified using a customized script in Definiens Developer XD software v2.5 (Definiens). The nucleus/cytoplasm value represents the ratio between the average nuclear fluorescence intensity of the cell population and the average cytoplasmic fluorescence intensity between their own nuclei.

Flow Cytometry and Cell Sorting
Seventy-two hours after transfection or electroporation, cells were trypsinized, washed twice with Dulbecco’s PBS, counted, and resuspended in an appropriate volume of sorting buffer (PBS containing 1% FBS and antibiotics). Prior to cell sorting, samples were filtered through a 70-μm filter to remove any cell clumps. Cell sorting was carried out in a Synergy 2L instrument (Sony Biotechnology). Flow-cytometry acquisition and analysis was performed in a BD LSR Fortessa Analyzer (BD Biosciences). A gating strategy was performed to remove clumps or doublets from the dataset (pulse geometry gating), to remove dead cells (DAPI viability gating), and to remove debris and other events of non-interest while preserving cells based on size and/or complexity (forward- and side-scatter gating).

Genomic DNA Extraction and PCR Analysis
Genomic DNA was extracted using standard procedures. Primers used are listed in Table S1.

Fluorescence In Situ Hybridization
For FISH analysis, HEK293, hMSC, and hiPSC cultures were first arrested in metaphase by incubation for 2–4 hr at 37°C with KaryoMAX Colcemid (0.1 μg/mL) (Thermo Fisher) and then harvested after treatment with a hypotonic salt solution. A break-apart EWSR1 FISH probe (Cytocell) was used to detect the t(11;22) chromosomal translocation. Chromosome spreads were left overnight at room temperature. Slides were dehydrated through a series of ethanol washes, denatured in the presence of 100 μL of NEB Buffer 2, in order to form heteroduplexes. Products were then processed with the T7 endonuclease I (NEB) and further purified on a Qiaquick Spin Column (Qiagen). A total of 350 ng of each PCR product was reannealed in a final volume of 20 μL of NEB Buffer 2, in order to form heteroduplexes. Products were then processed with the T7 endonuclease I (NEB) and separated on an 8% polyacrylamide Tris/borate/EDTA (TBE) gel. Gels were stained with SYBR Gold (Thermo Fisher) for 20 min and washed with 1× TBE for 10 min. Cas9-mediated cleavage efficiency (indel percentage) is calculated on the basis of the fraction of cleaved DNA, as determined by integrated intensity of gel bands. Images were acquired with the Gel Doc imaging system (Bio-Rad), and relative band intensities were quantified with ImageJ. NHEJ frequency was quantified using the formula 100 × (1 − (a/(a + b)))/1/2, where a is the band intensity of the cleavage products and b is the band intensity of the uncleaved PCR product.
Lentivirus Generation, Titration, and Transduction

Viruses were produced by transient plasmid transfection into HEK293 cells using the calcium phosphate method (Torres et al., 2011).

Statistical Analysis

Data from three or more independent experiments were analyzed by two-tailed unpaired t test. In the figures, significance is denoted by *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.

SUPPLEMENTAL INFORMATION

Supplemental Information includes Supplemental Experimental Procedures, six figures, and two tables and can be found with this article online at http://dx.doi.org/10.1016/j.stemcr.2017.04.014.

AUTHOR CONTRIBUTIONS

R.T.-R. and S.R.-P. designed and performed experiments, analyzed the data, and wrote the manuscript; M.M.-L., M.C.M., and A.G. assisted in the experiments and collected data; P.M. wrote the manuscript; J.C.C. and J.C.R. analyzed the data and commented on the manuscript; C.B. and J.C. commented on the manuscript.

ACKNOWLEDGMENTS

This work was supported by funds from the Spanish National Research and Development Plan, Instituto de Salud Carlos III, and FEDER (PI14/01884 to S.R.-P. and PI12/00425 to J.C.C.). R.T.-R. was supported by an international fellowship from Lady Tata Memorial Trust during 2016–2017.

REFERENCES

Audebert, M., Salles, B., and Calsou, P. (2004). Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining. J. Biol. Chem. 279, 55117–55126.

Audebert, M., Salles, B., Weinfeld, M., and Calsou, P. (2006). Involvement of polymerase kinase in a poly (ADP-ribose) polymerase-1-dependent DNA double-strand breaks rejoining pathway. J. Mol. Biol. 356, 257–265.

Blasco, R.B., Karaca, E., Ambrogio, C., Cheong, T.-C., Karayol, E., Minero, V.G., Voena, C., and Chiarle, R. (2014). Simple and rapid in vivo generation of chromosomal rearrangements using CRISPR/Cas9 technology. Cell Rep. 9, 1219–1227.

Brunet, E., Simsek, D., Tomishima, M., DeKlerver, R., Choi, V.M., Gregory, P., Urnov, F., Weinstock, D.M., and Jasim, M. (2009). Chromosomal translocations induced at specified loci in human stem cells. Proc. Natl. Acad. Sci. USA 106, 10620–10625.

Bueno, C., Montes, R., Catalina, P., Rodriguez, R., and Menendez, P. (2011). Insights into the cellular origin and etiology of the infant pro-B acute lymphoblastic leukemia with MLL-AF4 rearrangement. Leukemia 25, 400–410.

Castaño, J., Herrero, A.B., Bursen, A., González, F., Marchalek, R., Gutiérrez, N.C., and Menendez, P. (2016). Expression of MLL-AF4 or AF4-MLL fusions does not impact the efficiency of DNA damage repair. Oncotarget 7, 30440–30452.

Certo, M.T., Gwiazda, K.S., Kuhar, R., Sather, B., Curinga, G., Mandt, T., Braunl, M., Lambert, A.R., Baxter, S.K., Jacoby, K., et al. (2012). Coupling endonucleases with DNA end-processing enzymes to drive gene disruption. Nat. Methods 9, 973–975.

Chen, J.-M., Cooper, D.N., Férec, C., Kehler-Sawatzki, H., and Patrinos, G.P. (2010). Genomic rearrangements in inherited disease and cancer. Semin. Cancer Biol. 20, 222–233.

Chen, E., Pruett-Miller, S.M., Huang, Y., Gijoka, M., Duda, K., Taunton, J., Collingwood, T.N., Frodin, M., and Davis, G.D. (2011). High-frequency genome editing using ssDNA oligonucleotides with zinc-finger nucleases. Nat. Methods 8, 753–755.

Chen, Z., Jafar, L., Agyekum, D.G., Xiao, H., Wade, M.F., Kumaran, R.J., Spector, D.L., Bao, G., Porteus, M.H., Dynan, W.S., and Meiler, S.E. (2013). Receptor-mediated delivery of engineered nucleases for genome modification. Nucleic Acids Res. 41, e182.

Cong, L., Ran, F.A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P.D., Wu, X., Jiang, W., Marraffini, L.A., and Zhang, F. (2013). Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819–823.

Delatte, O., Zucman, J., Melot, T., Garau, X.S., Zucker, J.M., Lenoir, G.M., Ambros, P.F., Sheer, D., Turc-Carel, C., and Triche, T.J. (1994). The Ewing family of tumors—a subgroup of small-round-cell tumours defined by specific chimeric transcripts. N. Engl. J. Med. 331, 294–299.

Forster, A., Pannell, R., Drynan, L., Cano, F., Chan, N., Codrington, R., Daser, A., Lobato, N., Metzler, M., Nam, C.-H., et al. (2005). Chromosomal translocation engineering to recapitulate primary events of human cancer. Cold Spring Harb. Symp. Quant. Biol. 70, 275–282.

Gaj, T., Guo, J., Kato, Y., Sirk, S.J., and Barbas, C.F. (2012). Targeted gene knockout by direct delivery of zinc-finger nuclease proteins. Nat. Methods 9, 805–807.

Guryanova, O.A., and Levine, R.L. (2013). Advances in the development of animal models of myeloid leukemias. Semin. Hematol. 50, 145–155.

Howard, S.M., Yanez, D.A., and Stark, J.M. (2015). DNA damage response factors from diverse pathways, including DNA crosslink repair, mediate alternative end joining. PLoS Genet. 11, e1004943.

Iliakis, G., Murmann, T., and Soni, A. (2015). Alternative end-joining repair pathways are the ultimate backup for abrogated non-homologous end-joining and homologous recombination repair: implications for the formation of chromosome translocations. Mutat. Res. Genet. Toxicol. Environ. Mutagen 793, 166–175.

Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J.A., and Charpentier, E. (2012). A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816–821.
Kim, H., and Kim, J.-S. (2014). A guide to genome engineering with programmable nucleases. Nat. Rev. Genet. 15, 321–334.
Kim, S., Kim, D., Cho, S.W., Kim, J., and Kim, J.-S. (2014). Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res. 24, 1012–1019.
Kovar, H., Amatruda, J., Brunet, E., Burdach, S., Cidre-Aranaz, F., and de Alva, E. (2016). The second European interdisciplinary Ewing sarcoma research summit—a joint effort to deconstructing the multiple layers of a complex disease. Oncotarget 7, 8613–8624.
Li, K., Wang, G., Andersen, T., Zhou, P., and Pu, W.T. (2014). Optimization of genome engineering approaches with the CRISPR/Cas9 system. PLoS One 9, e105779.
Liang, X., Potter, J., Kumar, S., Zou, Y., Quintanilla, R., Snidharan, M., Carte, J., Chen, W., Roark, N., Ranganathan, S., et al. (2015). Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection. J. Biotechnol. 208, 44–53.
Liu, J., Gaj, T., Wallen, M.C., and Barbas, C.F. (2015). Improved cell-penetrating zinc-finger nuclease proteins for precision genome engineering. Mol. Ther. Nucleic Acids 4, e232.
Maddalo, D., Manchado, E., Concepcion, C.P., Bonetti, C., Vidigal, J.A., Han, Y.-C., Ogrodowski, P., Crippa, A., Rekhtman, N., de Stanischina, E., et al. (2014). In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system. Nature 516, 423–427.
Mali, P., Yang, L., Esvelt, K.M., Aach, J., Guell, M., DiCarlo, J.E., Norville, J.E., and Church, G.M. (2013). RNA-guided human genome engineering via Cas9. Science 339, 823–826.
McVey, M., Madut, D., and Sekelsky, J.J. (2004). End-joining repair of double-strand breaks in Drosophila melanogaster is largely DNA ligase IV independent. Genetics 168, 2067–2076.
Menendez, P., Bueno, C., and Wang, L. (2006). Human embryonic stem cells: a journey beyond cell replacement therapies. Cytotherapy 8, 530–541.
Minas, T.Z., Surdez, D., Javaheri, T., Tanaka, M., Howarth, M., Kang, H.-J., Han, J., Han, Z.-Y., Sax, B., Kream, B.E., et al. (2016). Combined experience of six independent laboratories attempting to create an Ewing sarcoma mouse model. Oncotarget 9, 422–434.
Muñoz-López, A., Romero-Moya, D., Prieto, C., Ramos-Mejía, V., Agraz-Doblas, A., Varela, I., Buschbeck, M., Palau, A., Carvajal-Vergara, X., Giorgetti, A., et al. (2016). Development refractoriness of MLL-rearranged human B cell acute leukemias to reprogramming into pluripotency. Stem Cell Rep. 7, 602–618.
Piganeau, M., Ghezraoui, H., De Cian, A., Guittat, L., Tomishima, M., Perrouault, L., René, O., Katibah, G.E., Zhang, L., Holmes, M.C., et al. (2013). Cancer translocations in human cells induced by zinc finger and TALE nucleases. Genome Res. 23, 1182–1193.
Ramakrishna, S., Kwaku Dad, A.-B., Beloor, J., Gopalappa, R., Lee, S.-K., and Kim, H. (2014). Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA. Genome Res. 24, 1020–1027.
Renouf, B., Piganeau, M., Ghezraoui, H., Jasins, M., and Brunet, E. (2014). Creating cancer translocations in human cells using Cas9 DSBs and nCAs9 paired nicks. Meth. Enzymol. 546, 251–271.
Rodriguez, R., Rubio, R., and Menendez, P. (2011). Modeling sarcomagenesis using multipotent mesenchymal stem cells. Cell Res. 21, 62–77.
Rodriguez-Perales, S., Torres-Ruiz, R., Suela, J., Acquadro, F., Martin, M.C., Yebra, E., Ramirez, J.C., Alvarez, S., and Cigudosa, J.C. (2015). Truncated RUNX1 protein generated by a novel t(1;21)(p32;q22) chromosomal translocation impairs the proliferation and differentiation of human hematopoietic progenitors. Oncogene 35, 125–134.
Sancho-Martinez, I., Nivet, E., Xia, Y., Hishida, T., Aguierre, A., Ocampo, A., Ma, L., Morey, R., Krause, M.N., Zembrzycki, A., et al. (2016). Establishment of human iPSC-based models for the study and targeting of glioma initiating cells. Nat. Commun. 7, 10743.
Simsek, D., and Jasins, M. (2010). Alternative end-joining is suppressed by the canonical NHEJ component Xrcc4-ligase IV during chromosomal translocation formation. Nat. Struct. Mol. Biol. 17, 410–416.
Torres, R., and Ramirez, J.C. (2009). A chemokine targets the nucleus: Cxcl12-gamma isoform localizes to the nucleolus in adult mouse heart. PLoS One 4, e7570.
Torres, R., García, A., Payá, M., and Ramirez, J.C. (2011). Non-integrative lentivirus drives high-frequency cre-mediated cassette exchange in human cells. PLoS One 6, e19794.
Torres, R., García, A., Jimenez, M., Rodriguez, S., and Ramirez, J.C. (2014a). An integration-defective lentivirus-based resource for site-specific targeting of an edited safe-harbour locus in the human genome. Gene Ther. 21, 343–352.
Torres, R., Martin, M.C., García, A., Cigudosa, J.C., Ramirez, J.C., and Rodriguez-Perales, S. (2014b). Engineering human tumour-associated chromosomal translocations with the RNA-guided CRISPR-Cas9 system. Nat. Commun. 5, 3964.
Van Deursen, J., Fornerod, M., Van Rees, B., and Grosveld, G. (1995). Cre-mediated site-specific translocation between nonhomologous mouse chromosomes. Proc. Natl. Acad. Sci. USA 92, 7376–7380.
Wray, J., Williamson, E.A., Singh, S.B., Wu, Y., Cogle, C.R., Weinstock, D.M., Zhang, Y., Lee, S.-H., Zhou, D., Shao, L., et al. (2013). PARP1 is required for chromosomal translocations. Blood 121, 4359–4365.
Yang, L., Guell, M., Byrne, S., Yang, J.L., De Los Angeles, A., Mali, P., Aach, J., Kim-Kiselak, C., Briggs, A.W., Rios, X., et al. (2013). Optimization of scarless human stem cell genome editing. Nucleic Acids Res. 41, 9049–9061.
Yoshimi, K., Kunihiro, Y., Kaneko, T., Nagahora, H., Voigt, B., and Mashimo, T. (2016). ssODN-mediated knock-in with CRISPR-Cas for large genomic regions in zygotes. Nat. Commun. 7, 10431.
Supplemental Information

Efficient Recreation of t(11;22) EWSR1-FLI1+ in Human Stem Cells Using CRISPR/Cas9

Raul Torres-Ruiz, Marta Martinez-Lage, Maria C. Martin, Aida Garcia, Clara Bueno, Julio Castaño, Juan C. Ramirez, Pablo Menendez, Juan C. Cigudosa, and Sandra Rodriguez-Perales
A

EWSR1 Off-target 1
(chromosome 14: -83517253)
AaTTGTTTTTAGTtGCCT aaG

EWSR1 Off-target 2
(chromosome 14: 71328829)
AATaGaTTTAGTATGCCT aaG

B

FLI1 Off-target 1
(chromosome 6: +155480)
CcaGCCTGGGCGATAGACCa caG

FLI1 Off-target 2
(chromosome 18: -63518093)
CcaGCCTGGGCGATAGACTG AGG
A

![Diagram of gene expression vectors](image)

- U6
- H1
- CMV
- P2A
- WPRE

LTR  sgE1  sgF2  Cas9  EGFP  LTR

1xNLS plasmid

2xNLS plasmid

Nucleoplasmin
NLS

SV40NLS

Cas9

B

1xNLS  2xNLS

- anti-Cas9
  - 165 KDa

- anti-human GAPDH
  - 37 KDa

C

- hiPSC negative control
- hiPSC electroporated Cy3
Figure S1. Flow cytometry analysis of eGFP expression achieved with different delivery systems in HEK293A cells and hMSCs. Representative eGFP flow cytometry profiles showing the transfection efficiency achieved with five distinct delivery approaches in HEK293A cells (A) and hMSCs (B). Non-transfected cells were used as negative controls. IDLV: Integrative Defective Lentivirus, LV: Lentivirus.

Figure S2. (A) Agarose-gel electrophoresis of translocation-specific PCR products from pooled HEK293 and hMSCs samples corresponding to the FLI1-EWSR1 fusion gene mapped at der(11) chromosome. (B) Representative agarose-gel electrophoresis of EWSR1-FLI1 and FLI1-EWSR1 RT-PCR products confirming the expression of both derivative fusion genes EWSR1-FLI1 and FLI1-EWSR1. Sanger sequencing chromatograms showing the breakpoint region in the fusion genes mapped at der(11) and der(22) in HEK293 cells. (C) Representative Western blot analysis of EWSR1-FLI1 chimeric protein in A673 Ewing sarcoma cell line and HEK293 cells. GAPDH was used as a loading control.

Figure S3. Off-target effects in HEK293A cells produced with different CRISPR approaches. Representative T7 endonuclease I cleavage assay in HEK293A cells after electroporation with the 2-plasmid, 1xNLS, 2xNLS, or RNP approaches. Non-electroporated cells are used as controls. Full-length PCR products are indicated by an open triangle; predicted positions of digestion products are indicated by filled triangles.

Figure S4. (A) Schematic representation of 1xNLS and 2xNLS versions of pLV-U6#1H1#2-C9G. (B) Representative Western blot analysis of Cas9 protein in HEK293 cells transfected with either 1xNLS or 2xNLS versions of pLV-U6#1H1#2-C9G. GAPDH was used as a loading control. (C) Representative flow cytometry analysis of Cy3 signals in hiPSCs transfected with a synthetic Cy3 labelled oligonucleotide.

Figure S5. (A) Representative gating strategy to remove clumps or doublets, dead cells and debris or other events of non-interest from the data set while preserving cells based on size and or complexity. This gating strategy was used in Figures S1 and S5. (B) Flow cytometry analysis of eGFP expression in HEK293A cells after nucleofection with increasing amounts of RNPs.

Figure S6. Representative FISH images showing t(11;22)+ hiPSC after 8 weeks in culture. Arrows indicate separated signals corresponding to the der(22) and der(11) breakpoint regions. Interphase nuclei are counterstained with DAPI. Scale bars, 10 µm.
# 2 plasmids vs 1 plasmid

| Compound   | assay #1 | assay #2 | assay #3 | assay #4 | total |
|------------|---------|---------|---------|---------|-------|
| Calcium Phos |         |         |         |         |       |
| E1 + F2 293 cells | 3 | 242 | 1.24 | 3 | 256 | 1.17 | 2 | 205 | 0.98 | 8 | 703 | 1.14 | 1.14 |
| E1F2 1 plasmid | 6 | 245 | 2.45 | 5 | 225 | 2.22 | 5 | 185 | 2.70 | 16 | 655 | 2.44 | 2.44 |
| 1 plasmid | 8 | 220 | 3.64 | 9 | 243 | 3.70 | 6 | 197 | 3.05 | 23 | 660 | 3.48 | 3.48 |
| IDLV | 1 | 223 | 0.45 | 0 | 210 | 0.00 | 0 | 187 | 0.00 | 1 | 620 | 0.16 | 0.16 |
| L3000 | 4 | 257 | 1.56 | 5 | 238 | 2.10 | 3 | 221 | 1.36 | 12 | 716 | 1.68 | 1.68 |
| E1 + F2 hMSC cells | 0 | 450 | 0.00 | 1 | 500 | 0.20 | 1 | 471 | 0.21 | 1 | 431 | 0.23 | 2 | 1852 | 0.11 | 0.11 |
| E1F2 1 plasmid | 3 | 450 | 0.67 | 3 | 500 | 0.60 | 4 | 467 | 0.86 | 3 | 487 | 0.62 | 13 | 1904 | 0.68 | 0.12 |
| 1 plasmid | 0 | 450 | 0.00 | 1 | 500 | 0.20 | 1 | 471 | 0.21 | 1 | 431 | 0.23 | 2 | 1852 | 0.11 | 0.11 |

## Delivery method

| Compound   | assay #1 | assay #2 | assay #3 | assay #4 | total |
|------------|---------|---------|---------|---------|-------|
| Calcium Phos |         |         |         |         |       |
| hMSC cells | 0 | 387 | 0.00 | 0 | 264 | 0.00 | 0 | 431 | 0.00 | 0 | 1082 | 0.00 | 0.00 |
| Neon | 3 | 311 | 0.96 | 4 | 300 | 1.33 | 3 | 238 | 1.26 | 10 | 849 | 1.18 | 0.20 |
| L3000 | 5 | 227 | 2.20 | 7 | 219 | 3.20 | 5 | 209 | 2.39 | 17 | 655 | 2.59 | 0.53 |
| IDLV | 1 | 341 | 0.29 | 0 | 223 | 0.00 | 1 | 500 | 0.20 | 2 | 1064 | 0.19 | 0.15 |
| L3000 | 3 | 215 | 1.39 | 3 | 298 | 1.01 | 4 | 350 | 1.14 | 10 | 863 | 1.16 | 0.20 |

## TORRES-RUIZ et al. Sup. Table. 1

| Compound   | assay #1 | assay #2 | assay #3 | assay #4 | total |
|------------|---------|---------|---------|---------|-------|
| Calcium Phos |         |         |         |         |       |
| L3000 | 0 | 450 | 0.00 | 1 | 500 | 0.20 | 1 | 471 | 0.21 | 1 | 431 | 0.23 | 2 | 1852 | 0.11 | 0.11 |
| 1 plasmid | 3 | 450 | 0.67 | 3 | 500 | 0.60 | 4 | 467 | 0.86 | 3 | 487 | 0.62 | 13 | 1904 | 0.68 | 0.12 |

| Compound   | assay #1 | assay #2 | assay #3 | assay #4 | total |
|------------|---------|---------|---------|---------|-------|
| Calcium Phos |         |         |         |         |       |
| L3000 | 0 | 450 | 0.00 | 1 | 500 | 0.20 | 1 | 471 | 0.21 | 1 | 431 | 0.23 | 2 | 1852 | 0.11 | 0.11 |
| 1 plasmid | 3 | 450 | 0.67 | 3 | 500 | 0.60 | 4 | 467 | 0.86 | 3 | 487 | 0.62 | 13 | 1904 | 0.68 | 0.12 |

---

** p-value

ns
### Sorting

|                | assay #1 | assay #2 | assay #3 | total | average | SD | p-value |
|----------------|----------|----------|----------|-------|---------|----|---------|
|                | positive | total counted | %       | positive | total counted | %       | positive | total counted | average | SD | p-value |
| Non Sorted     | 2        | 306 | 0.65 | 2        | 311 | 0.64 | 3        | 294 | 1.02 | 7        | 911 | 0.77 | 0.22 | Non sorted | ns |
| Sorted Low     | 1        | 299 | 0.33 | 3        | 315 | 0.95 | 0        | 268 | 0.00 | 4        | 882 | 0.45 | 0.48 | Low | * |
| Sorted High    | 5        | 273 | 1.83 | 5        | 303 | 1.65 | 4        | 233 | 1.72 | 14       | 809 | 1.73 | 0.09 | High | ** |

|                | assay #1 | assay #2 | assay #3 | total | average | SD | p-value |
|----------------|----------|----------|----------|-------|---------|----|---------|
|                | positive | total counted | %       | positive | total counted | %       | positive | total counted | average | SD | p-value |
| Non Sorted     | 1        | 312 | 0.32 | 0        | 325 | 0.00 | 1        | 294 | 0.34 | 2        | 931 | 0.22 | 0.19 | Non sorted | ns |
| Sorted         | 2        | 283 | 0.71 | 3        | 315 | 0.95 | 2        | 247 | 0.81 | 7        | 845 | 0.83 | 0.12 | ns |

### 1xNLS vs 2xNLS

|                | assay #1 | assay #2 | assay #3 | total | average | SD | p-value |
|----------------|----------|----------|----------|-------|---------|----|---------|
|                | positive | total counted | %       | positive | total counted | %       | positive | total counted | average | SD | p-value |
| 293 cells      | 3        | 515 | 0.58 | 1        | 516 | 0.19 | 4        | 557 | 0.72 | 8        | 1588 | 0.50 | 0.27 | 1xNLS | ns |
|                | 9        | 480 | 1.88 | 5        | 532 | 0.94 | 18       | 737 | 2.44 | 32       | 1749 | 1.83 | 0.76 | 2xNLS | ns |

|                | assay #1 | assay #2 | assay #3 | total | average | SD | p-value |
|----------------|----------|----------|----------|-------|---------|----|---------|
| hMSC cells     | 1        | 545 | 0.18 | 0        | 527 | 0.00 | 0        | 501 | 0.00 | 1        | 1573 | 0.06 | 0.11 | 1xNLS | ns |
|                | 2        | 495 | 0.40 | 2        | 543 | 0.37 | 3        | 500 | 0.60 | 7        | 1538 | 0.46 | 0.13 | 2xNLS | * |

1xNLS vs 2xNLS
# ssODNs

| ssODN | assay #1 | assay #2 | assay #3 | total |
|-------|--------|--------|--------|------|
|       | positive | total counted | % | positive | total counted | % | positive | total counted | % | average | SD | p-value |       |
| 60    | 1       | 304       | 0.33 | 1       | 300       | 0.33 | 3       | 297       | 0.34 | 3       | 901 | 0.33 | 0.01 | 60 | ns |
| 90    | 1       | 347       | 0.29 | 1       | 260       | 0.38 | 1       | 308       | 0.32 | 3       | 915 | 0.33 | 0.05 | 90 | ns |
| 120   | 2       | 301       | 0.66 | 1       | 300       | 0.33 | 2       | 310       | 0.65 | 5       | 911 | 0.55 | 0.19 | 120 | * |
| 150   | 5       | 310       | 1.29 | 3       | 300       | 1.00 | 3       | 290       | 1.04 | 10      | 900 | 1.11 | 0.16 | 150 | empty |
| 180   | 2       | 346       | 0.58 | 2       | 305       | 0.66 | 1       | 280       | 0.36 | 5       | 931 | 0.54 | 0.15 | 180 | empty |
| no ssODN | 1       | 302       | 0.33 | 0       | 300       | 0.00 | 0       | 315       | 0.00 | 1       | 917 | 0.11 | 0.19 | empty | empty |

**hMSC cells**

| ssODN | assay #1 | assay #2 | assay #3 | total |
|-------|--------|--------|--------|------|
|       | positive | total counted | % | positive | total counted | % | positive | total counted | % | average | SD | p-value |       |
| e1f2  | NA      | NA      | 2.29 | 8       | 250       | 3.20 | 10      | 382       | 2.62 | 25      | 938 | 2.67 | 0.46 | e1f2 + f1e2 | 0.0027 | ** |
| f1e2  | NA      | NA      | 0.20 | 0       | 300       | 0.00 | 2       | 315       | 0.64 | 3       | 1115 | 0.27 | 0.32 | empty | empty | empty |
| empty | NA      | NA      | 0.00 | 2       | 315       | 0.64 | 3       | 1115       | 0.27 | 3       | 1115 | 0.27 | 0.32 | empty | empty | empty |

**NA:** Not Applicable
## DNA-end processing factors

| Factors   | assay #1 |          | assay #2 |          | assay #3 |          | total    |          | average | SD  | p-value |
|-----------|----------|----------|----------|----------|----------|----------|----------|----------|---------|------|---------|
|           | positive | total    | %        | positive | total    | %        | positive | total    |         |      |         |
| empty     | 8        | 284      | 2.82     | 6        | 249      | 2.41     | 7        | 261      | 2.68    | 21   | 794     | 2.64   | 0.21 | 0.0022 ** |
| AICDA     | na       | na       | na       | na       | na       | na       | na       | na       | na      | na   | na      | na     | na   | empty |
| ARTEMIS   | 5        | 352      | 1.42     | 4        | 294      | 1.36     | 5        | 308      | 1.62    | 14   | 954     | 1.47   | 0.14 | 0.0306 *  |
| PARP1     | 10       | 307      | 3.26     | 9        | 273      | 3.30     | 9        | 281      | 3.20    | 28   | 861     | 3.25   | 0.05 | empty |
| TREX2     | 9        | 304      | 2.96     | 3        | 297      | 1.01     | 6        | 285      | 2.10    | 18   | 886     | 2.03   | 0.98 | empty |
| DCLREI    | 2         | 280      | 2.86     | 7        | 257      | 2.72     | 6        | 241      | 2.49    | 21   | 778     | 3.38   | 0.43 | empty |
| FEN1      | 7         | 292      | 2.40     | 6        | 237      | 2.53     | 4        | 189      | 2.12    | 17   | 718     | 2.70   | 0.19 | empty |
| MRE11     | 7         | 225      | 3.11     | 11       | 308      | 3.57     | 8        | 271      | 2.95    | 26   | 804     | 3.23   | 0.32 | empty |

**293 cells**

AICDA & ARTEMIS has a significant p-value but with a decreasing translocation efficiency

| Factors   | assay #1 |          | assay #2 |          | assay #3 |          | total    |          | average | SD  | p-value |
|-----------|----------|----------|----------|----------|----------|----------|----------|----------|---------|------|---------|
|           | positive | total    | %        | positive | total    | %        | positive | total    |         |      |         |
| empty     | 1        | 315      | 0.32     | 1        | 301      | 0.33     | 1        | 289      | 0.35    | 3    | 905     | 0.33   | 0.01 | 0.1248 ns |
| hMSC cells| na       | na       | na       | na       | na       | na       | na       | na       | na      | na   | na      | na     | na   | empty |
| ARTEMIS   | na       | na       | na       | na       | na       | na       | na       | na       | na      | na   | na      | na     | na   | empty |
| PARP1     | 2        | 321      | 0.62     | 3        | 362      | 0.83     | 2        | 278      | 0.72    | 7    | 961     | 0.73   | 0.10 | 0.0206 *  |
| TREX2     | 2        | 301      | 0.66     | 3        | 387      | 0.77     | 2        | 291      | 0.69    | 7    | 979     | 0.72   | 0.06 | TREX2 0.0056 ** |
| DCLREI    | na       | na       | na       | na       | na       | na       | na       | na       | na      | na   | na      | na     | na   | empty |
| FEN1      | na       | na       | na       | na       | na       | na       | na       | na       | na      | na   | na      | na     | na   | empty |
| MRE11     | na       | na       | na       | na       | na       | na       | na       | na       | na      | na   | na      | na     | na   | empty |

**hMSC cells**

AICDA & ARTEMIS has a significant p-value but with a decreasing translocation efficiency
## RNP Cas9

| 2 plasmids | 293 cells | 2NLS | RNP |
|------------|-----------|------|-----|
| 0          | 213       | 0.00 | 0   |
| 4          | 301       | 1.33 | 1.33|
| 6          | 203       | 2.96 | 2.96|

| hiPSC      | RNP + ssODN | 2NLS plasmid | RNP + ssODN |
|------------|-------------|---------------|-------------|
| 3          | 261         | 1.15          | 1.15        |
| 1          | 353         | 0.28          | 0.28        |

### hMSC Cells

| 2 plasmids | 2NLS | RNP |
|------------|------|-----|
| 0          | 335  | 0.00|
| 3          | 327  | 0.92|

### hiPSC

| 2 plasmids | 2NLS | RNP |
|------------|------|-----|
| 3          | 261  | 1.15|
| 1          | 353  | 0.28|

### hMSC Cells

| 2 plasmids | 2NLS | RNP + TREX2 | RNP + PARP1 | RNP + ssODN |
|------------|------|-------------|--------------|-------------|
| 0          | 335  | 0.00        | 0.00         | 0.00        |
| 3          | 327  | 0.92        | 0.92         | 0.92        |

### hiPSC

| 2 plasmids | 2NLS | RNP + TREX2 | RNP + PARP1 | RNP + ssODN |
|------------|------|-------------|--------------|-------------|
| 3          | 261  | 1.15        | 1.15         | 1.15        |
| 1          | 353  | 0.28        | 0.28         | 0.28        |

### Statistical Significance

- **p-value**
- * p-value < 0.05
- ** p-value < 0.01
- *** p-value < 0.001

| RNP + ssODN | RNP + PARP1 | RNP + TREX2 | RNP |
|-------------|-------------|-------------|-----|
| 0.0033      | 0.7517      | 0.0004      | 0.0007 |

### Additional Notes

- * indicates significance at p < 0.05.
- ** indicates significance at p < 0.01.
- *** indicates significance at p < 0.001.
| Name        | Application        | Sequence                        |
|-------------|--------------------|---------------------------------|
| OTf2 Fw     | FLI1 off target    | GGAGGAAGAGAAGTGAAGT             |
| OTf2 Rv     | FLI1 off target    | GCAGAGGAAGAGAAGTGAAGT           |
| OTf4 Fw     | FLI1 off target    | CTGGAGGAAGAGAAGTGAAGT           |
| OTf4 Rv     | FLI1 off target    | CTGGAGGAAGAGAAGTGAAGT           |
| OTe1 Fw     | EWSR1 off target   | TCGTTTCGCCCTAGAGAAGT            |
| OTe1 Rv     | EWSR1 off target   | TCGTTTCGCCCTAGAGAAGT            |
| OTe7 Fw     | EWSR1 off target   | CGAGAAGAAGAGAAGTGAAGT           |
| OTe7 Rv     | EWSR1 off target   | CGAGAAGAAGAGAAGTGAAGT           |
| EWSR1 Fw    | EWSR1 on-target    | GCTGCCTCCGCACACGACGG            |
| EWSR1 Rv    | EWSR1 on-target    | GCTGCCTCCGCACACGACGG            |
| FLII Fw1    | FLI1 on-target     | TGGAAGACCTTGAGACCAT             |
| FLII Fw2    | FLI1 on-target     | TGGAAGACCTTGAGACCAT             |
| EWSR1 Fw2   | Translocation detection | AGGACACACTTTTGGGCA            |
| FLII Fw2    | Translocation detection | AGGACACACTTTTGGGCA            |
| ssODN_e1f2 60 ODN |                     | CCGAGGCTCTGCTTTTGATGAT         |
| ssODN_e1f2 90 ODN |                     | CCGAGGCTCTGCTTTTGATGAT         |
| ssODN_e1f2 120 ODN |                     | CCGAGGCTCTGCTTTTGATGAT         |
| ssODN_e1f2 150 ODN |                     | CCGAGGCTCTGCTTTTGATGAT         |
| ssODN_e1f2 180 ODN |                     | CCGAGGCTCTGCTTTTGATGAT         |
| sgEWSR1_1 single-guide sequence |                 | AATTTGTTTTAGAGCT TGG          |
| sgFLI1_2 single-guide sequence |                 | CTOGGCTGGGACGACGG AAG          |

TORRES-RUIZ et al. Sup. Table. 2
Table S1: Details of the FISH results included in this study.

Table S2: Oligonucleotide, ssODN, and sgRNA sequences used in this study.
SUPPLEMENTARY EXPERIMENTAL PROCEDURES

Transfection and Electroporation
Cells were transfected with endotoxin-free DNA (Qiagen) in 6-well plates. Calcium-phosphate-based transfection was performed as previously described (Torres et al., 2014a). Briefly, HEK293A cells were seeded and grown to confluence, and then transfections were performed with 6 µg plasmid DNA mixed with CaCl2. After 48-72 hours, cells were processed for subsequent analysis. For electroporation, the Neon Transfection System was used (Thermo Fisher Sci). Confluent hMSCs, hiPSCs and HEK293A cells were trypsinized, resuspended in R solution, and electroporated using the following conditions. For hMSCs, 10-µl tips were used to electroporate 1×10^5 cells with a single 40-ms pulse of 990 V. For HEK293A cells, 4×10^5 cells were electroporated with 10-µl tips using three 10-ms pulses of 1245 V. Finally, hiPSCs were electroporated with 10-µl tips using 2×10^5 cells with three 5-ms pulses of 1400 V. After electroporation, cells were seeded in a 24-well plate containing pre-warmed medium. When required, cells were sorted 72 h post-transfection. For co-transfection experiments, 200 pmol of ssODN (IDT) or end processing plasmids were included.

Immunofluorescence
Immunofluorescence was carried out as previously described, with modifications (Torres and Ramirez, 2009). Briefly, after nucleofection, cells were seeded onto 8-well glass bottom µ-Slides (Ibidi). After 72 h, cells were washed twice with PBS and fixed 10 min in 4% paraformaldehyde, permeabilized with 0.5% TritonX-100/PBS, and blocked with 4% normal goat serum. For Cas9 studies, samples were incubated overnight at 4°C with anti-Cas9 antibody (1/500 dilution, 7A9-3A3, Active Motif) and then for 1 h at RT with Alexa-fluor-555 secondary antibody (dilution 1/1000, Molecular Probes). For pluripotency-associated markers, hiPSCs were incubated overnight at 4°C with anti-OCT4 (1/500 dilutions, Cell Signaling Tech) or anti-SSEA4 antibodies (1/500 dilutions, MC-813-70, StemCell Tech) and then 1h at RT with Alexa-fluor-555 and Alexa-fluor-647 secondary antibodies in the darkness. Nuclei were counterstained with DAPI, and samples air-dried and mounted in gelatin (Sigma Aldrich). Images were captured with a Leica SP5 confocal laser-scanning microscope.

Genomic DNA Extraction and PCR Analysis
Genomic DNA was extracted using standard procedures. Briefly, 5-10×10^6 cells were either trypsinized or scraped, washed in PBS, pelleted, and lysed in 100 mM NaCl, Tris (pH 8.0) 50 mM, EDTA 100 mM, and 1% SDS. After overnight digestion at 56°C with 0.5 mg/ml of proteinase K (Roche), DNA was cleaned by precipitation with saturated NaCl, and the clear supernatant was precipitated with isopropanol, washed with 70% ethanol, air-dried, and resuspended overnight at
RT in 1xTE buffer. Serial DNA dilutions were quantified with a NanoDrop 1000 Spectrophotometer (Thermo Scientific). Standard PCR was performed under the following conditions: denaturation at 95°C for 1 min followed by 30 cycles of denaturation at 94°C for 30 s, annealing at 62.5°C for 30 s, extension at 72°C for 60 s, and a final extension of 5 min at 72°C. Primers used are listed in Table S1.

Lentivirus Generation, Titration, and Transduction
Viruses were produced by transient plasmid transfection into HEK293T cells using the calcium phosphate method (Torres et al., 2011). Briefly, cells were seeded at 1.1×10⁷ cells/dish in 15-cm dishes the day before transfection. Cells were transfected using calcium phosphate with 3 μg pRSV-Rev, 3.75 μg pMD.2G (VSV-G), 13 μg pMDLg/pRRE (or 13 μg pMDLg/pD64VRRE for production of non-integrative lentiviral vectors), and 35 μg of transfer plasmid (pLVX-U6-sgRNA⁸¹-H1-sgRNA⁸²-Cas9-2A-eGFP). The medium was collected after 48 h, cleared by low-speed centrifugation, and filtered through 0.45-μm pore PVDF filters (Millipore). Viral stocks were concentrated by ultracentrifugation at 20,000 rpm for 2 h at 16°C. Pellets containing lentivirus were air-dried and resuspended overnight at 4°C in 400 μl of medium. Viral titers in HEK293T cells transduced with vectors expressing fluorescent proteins were determined by FACS analysis (transduction units/ml). In the absence of a fluorescent reporter, titer was estimated by qPCR of particles in supernatants (particles/ml). Values ranged from 10⁷ to 10⁸ TU/ml and were at a TU/particle ratio of 1:100. Cells were transduced at different multiplicities of infection in medium containing Polybrene (8 μg/ml final concentration). Cells were incubated at 37°C for 6 h, and the viral supernatant was then replaced with fresh medium and analysed 72 h later.